Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-label, Parallel Group Study to Investigate Olaparib Safety and Tolerability, Efficacy and Pharmacokinetics in Paediatric Patients With Solid Tumours

NCT04236414 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04236414
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04236414 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-label, Parallel Group Study to Investigate Olaparib Safety and Tolerability, Efficacy and Pharmacokinetics in Paediatric Patients With Solid Tumours
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
January 14, 2020
Completion date
February 4, 2025
Enrollment
16 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumours